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ABSTRACT
Background: Intravenous disodium pamidronate has been described in the
treatment of several osteopathies. Although tolerability has been found to be
good in clinical trials, some mild to serious adverse events (AEs) have been
reported.
Objectives: The aims of this study were to analyze the tolerability of IV
pamidronate in patients being treated for osteoporosis and other metabolic
osteopathies and to describe particular patients with relative contraindica-
tions, because such cases are not commonly seen in daily clinical practice.
Methods: We performed a retrospective analysis of patients with different
osteopathies who were administered IV infusions of pamidronate at doses ranging
from 15 to 90 mg/infusion and 15 to 900 mg/year. The study was conducted in
patients who had received treatment at the Institute of Metabolic Investigations,
University of Salvador, Buenos Aires, Argentina, between January 1995 and
December 2003.  To rule out dose-related AEs, a comparison was made between
patients who received fewer IV infusions and had cumulative doses of 120 to
180 mg/y (less frequent administration [LFA] group) and those patients who
received regular infusions and had cumulative doses of >180 mg/year (frequent
administration [FA] group). To confirm data obtained from medical records and
to assess the occurrence of AEs, attempts were made to interview all patients
by phone. The following information was verified for each patient included in
the study: the reason for treatment, documented evidence of current diagnos-
tic criteria, and whether the dose administered was adequate to treat the
patient’s condition.
Results: Six hundred eight patients (464 [76.3%] women, 144 [23.7%] men;
mean [SD] age, 69 [10] years) with various osteopathies (osteoporosis, 367
[60.4%] of the patients; Paget’s disease, 172 [28.3%]; Sudeck’s disease, 63
[10.4%]; multiple myeloma, 3 [0.5%]; and bone metastases, 3 [0.5%]) were
administered a total of 2933 IV infusions of pamidronate during the study period.
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We were able to confirm the clinical records of 69.4% (422/608) of the patients by
telephone survey; 29.9% (124/415) of those patients experienced extraskeletal
AEs (most commonly fever and flu-like symptoms [eg, headache, malaise, fatigue,
chills, and asthenia]). The percentage of patients reporting AEs was significantly
higher for the LFA group than that of the FA group (91.2 vs 19.5; P < 0.001),
although factors other than the frequency of treatment might have had a bear-
ing on this finding. All AEs were mild and transient in both groups of patients,
and there were no reports of jaw osteonecrosis in either group. It should be
noted that although LFA patients received lower doses of pamidronate per infu-
sion than the FA group, they had higher cumulative doses/year. Biochemical
variables for the entire study population were compared with baseline mea-
surements, and no significant changes in mean values were observed. Both
serum calcium and 25-hydroxy vitamin D levels remained within normal ranges.
On the other hand, there was a transient decrease in white blood cell count
(WBCC) in 73 (12.0%) patients, and leukopenia was observed in 8 (1.3%) patients.
However, 5 of the 6 patients who were leukopenic at the beginning of treatment
had normal WBCCs during follow-up. Platelet count decreased significantly in 
20 (3.3%) patients, and 5 (0.8%) patients developed thrombocytopenia. Serum
creatinine (sCreat) levels increased significantly in 91 (15.0%) patients. This
increase was transient and within normal limits (0.6–1.2 mg/dL) in 79 (86.8%) of
those patients but persistent in the other 12 (13.2%), all of whom received
higher doses of pamidronate or had other risk factors for renal failure such as
advanced age, diabetes, multiple myeloma, or an obstructor disease. Baseline
sCreat level for 7 of these 12 patients was >1.20 mg/dL.
Conclusions: Pamidronate administered IV was well tolerated when used for
treating osteoporosis or other metabolic osteopathies in our study population.
The clinical AEs observed with IV pamidronate administration were not serious
and hematologic changes were mild, transient, and not associated with dose,
time of treatment, or any particular underlying disease. An increase in sCreat
level was the most frequent biochemical complication and was found in
patients with additional risk factors for renal failure and particular diseases.
Whether certain patients with risk factors for osteoporosis may require even
fewer IV administrations of the drug is an issue that remains to be elucidated.
(Curr Ther Res Clin Exp. 2007;68:1–22) Copyright © 2007 Excerpta Medica, Inc.
Key words: adverse events, pamidronate, osteoporosis, osteopathy, 
tolerability.
INTRODUCTION
The use of IV disodium pamidronate has been described in the treatment of sev-
eral osteopathies, including Paget’s disease of the bone, bone metastases,
malignant hypercalcemia, and multiple myeloma.1–5 All of these medical condi-
tions are characterized by high bone turnover rates; from the amount
absorbed, patients have greater pamidronate fractions in bone than in soft tis-
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sues and body fluids.6 Although tolerability has been found to be good in clini-
cal trials, some mild and some serious adverse events (AEs) have been
reported in the literature.7–11
Slow IV pamidronate infusions have been tested in the treatment of primary
and secondary osteoporosis12–19 for reasons associated with adherence or to
avoid the gastrointestinal AEs frequently observed when the drug is admini-
stered orally.20–22 In Europe and Latin America, IV administration has been
researched and is used for the treatment of osteoporosis when the oral route is
inadequate.12,13 It should be noted, however, that indications for the treatment
of osteoporosis with pamidronate are not globally uniform. In some countries,
oral formulations, which have been available commercially since 1987, have
been approved for this purpose while IV pamidronate infusions might only be
administered to patients with underlying malignancy according to the instruc-
tions in the package insert approved by Health Authorities.
The use of IV pamidronate in osteoporosis might be encouraged by pub-
lished reports suggesting that this treatment schedule reduces the rate of
fractures in secondary osteoporosis23 and by the decreased cost of generic IV
formulations. This mode of administration entails the use of lower doses of
pamidronate than those that are used for treating malignant diseases and
results in different profiles of exposure to the drug for skeletal and extraskele-
tal tissues.24 In this regard, the general tolerability of IV pamidronate has not
been clearly described.
Therefore, to make our data available regarding the tolerability of IV pami-
dronate in the management of osteoporosis and other metabolic osteopathies
treated with similar schedules, we reported our 8-year clinical experience with
this treatment. We have included cases with relative contraindications to the
use of this drug, such as previous renal or hematologic abnormalities, which we
believe are of special interest in clinical practice.
PATIENTS AND METHODS
The medical records and biochemical data of patients treated with IV
pamidronate for various osteopathies and followed up at our center, the Institute
of Metabolic Investigations, University of Salvador, Buenos Aires, Argentina,
between January 1995 and December 2003 were retrospectively analyzed.
Informed written consent to the use of their clinical data for scientific purposes
and agreement to participate in follow-up were obtained from all patients on
enrollment at our institution. Compliance with standard operative procedures
approved by the institute was ensured by clinical research specialists at all times
during the observation period. With the approval of our institution’s ethics com-
mittee, attempts were made to contact all patients by telephone to confirm the
data in their medical records and to avoid underestimating the actual prevalence
of AEs. When the survey was conducted, the period of time elapsed since the end
of treatment ranged from 6 months to 7 years.
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Because the crystalline structure of pamidronate might affect its stability
and other physical and chemical properties, the active principle used in this
study was pamidronic acid,* which was manufactured at a plant in Pilar, a
province of Buenos Aires, Argentina. The formulations, either in solution or
lyophilized, were diluted in 400 to 500 mL of 5% dextrose or isotonic saline in
volumes adequate for IV drip administration for 3 to 4 hours.
The following information was verified for each patient included in the study:
the reason for treatment, documented evidence of current diagnostic criteria,
and whether the dose administered was adequate to treat the patient’s condi-
tion based on manufacturers’ instructions in the package insert approved by
the Health Authorities and/or published trials.1–5,12–19 These data were retrieved
from the records of our center’s IV pamidronate infusion service. The existence
of potential relative contraindications to this treatment, such as previous
leukopenia or risk factors for renal failure, was also investigated and included
in the data analysis.
AEs were identified from the source documents, and their severity was deter-
mined according to the Committee for Proprietary Medicinal Products,
International Conference on Harmonisation (377/95).25 We reported all symp-
toms and clinical signs recorded during follow-up, even though the cause-effect
relationship was not established in all cases.
The following laboratory values were measured for all the patients: white
blood cell count (WBCC), with leukopenia defined as <4000 cells/mL; platelet
count (PlatC), with thrombocytopenia defined as <150,000 platelets/mL; serum
creatinine (sCreat) level; serum aspartate aminotransaminase and alanine amino-
transaminase activities; serum calcium level obtained by ion selective electrode
(Synchron CX3 Delta Beckman Instruments Inc., Brea, California; normal range,
8.5–10.5 mg/dL); and serum 25-hydroxy vitamin D (25-HVD) level, by radioim-
munoassay (Diasorin, Stillwater, Minnesota; normal range, 20–45 ng/mL). Our
institution used international quality assurance systems (Randox International
Quality Assessment Scheme, Antrim, United Kingdom, and Bureau Veritas
Quality International, certification via Centralab, Buenos Aires, Argentina) to
determine these biochemical values.
Taking into account the biological and the analytical variation coefficients of
these measurements, the following outcomes were considered clinically signifi-
cant: a decrease in WBCC >18.2%, a decrease in PlatC >16.2%, and an increase in
sCreat level >8.13%.26–28 Results were stratified in increasing degrees of severity
according to the magnitude of the difference between lowest or highest values
and previous control values. Decreases in WBCC >18.2% to 20% were described as
mild; further decreases were ranked in increasing degrees of severity: >20% to
30%, >30% to 40%, >40% to 50%, and >50%. A drop in PlatC >16.2% to 20% was con-
*Manufacturers: generic formulations: American Pharmaceutical Partners (Schaumberg, Illinois) and
Mayne Pharma (Melbourne, Australia); branded formulations: Aminomux® (Gador SA, Buenos Aires,
Argentina) and Panorin® (Han-Lim, Seoul, South Korea).
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sidered mild, and 2 increasing levels of severity were defined between >20% and
30% and >30%. An increase in sCreat level was considered mild when the differ-
ence between the maximum level recorded and the previous measurement was
>8.13% to 10.9%, with increasing degrees of severity set between >10.9% and 20%,
>20% and 40%, >40% and 50%, >50% and 60%, and >60%. In the case of serum
transaminase activities, any increase observed was considered significant.
As with the clinical AEs, all abnormalities detected in biochemical values
were recorded, although a causal relationship was not established in all cases.
Once the information regarding clinical and biochemical AEs had been gath-
ered, the data were regrouped to make comparisons between the following peri-
ods: 0 to 90 days before initial study drug administration (pretreatment con-
trol), 0 to 90 days after initial administration, and every 90 days thereafter for
1 year (±1 month).
To rule out dose-related AEs, a comparison was made between patients who
received fewer IV infusions and had cumulative doses of 120 to 180 mg/year (less
frequent administration [LFA] group) and those patients who received regular
infusions and had cumulative doses of >180 mg/year (frequent administration [FA]
group).
Statistical Analysis
We reported the mean (95% CI) changes observed in certain biochemical
properties and described patients whose laboratory values were significantly
altered at some point during follow-up. These changes were analyzed with
respect to the following variables: dosage administered per infusion, total dose
accumulated during treatment, and condition treated. The groups were com-
pared using the χ2 test or analysis of variance, depending on whether the distri-
bution of the variables was nonparametric or Gaussian, respectively. Correlation
coefficients were calculated according to Spearman’s test and reported when
clinically relevant. Clinical AEs were reported as a percentage of the patients
interviewed by telephone. Other data were reported as a percentage of the
entire study population and by the least-squares adjusted curve of the mean
(95% CI). In-treatment data points were excluded if >20% were missing with
respect to initial data. Laboratory data were analyzed using the Student t test for
paired samples or according to the study test for mean differences, as appropri-
ate. P < 0.05 was considered statistically significant. All statistical analysis was
performed with Statistica version 5.5 (Statsoft Inc., Tulsa, Oklahoma). 
RESULTS
Clinical Data
Six hundred eight patients (464 [76.3%] women, 144 [23.7%] men; mean [SD]
age, 69 [10] years) were administered a total of 2933 IV pamidronate infusions
during an 8-year follow-up period for the treatment of various osteopathies: 367
(60.4%) of patients had osteoporosis, 172 (28.3%) Paget’s disease of the bone,
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63 (10.4%) Sudeck’s disease, 3 (0.5%) multiple myeloma, and 3 (0.5%) metasta-
tic cancer. Doses administered ranged from 15 to 90 mg/infusion and from 15 to
900 mg/y (Table I).
We were able to confirm the clinical records of 69.4% (422/608) of the
patients by telephone survey. The AEs confirmed by the survey are shown in
Table II. Seven of those 422 patients died after follow-up and prior to the phone
interview for reasons that were considered to be unrelated to treatment. All the
deaths occurred long after the treatment and there was no evidence in any of
the medical records to relate the cause of death to the pharmacologic effects of
pamidronate.
In the surveyed population, a minority (16.1% [68]) were assigned to the LFA
group due to their medical condition or to premature discontinuation of treat-
ment. Unexpectedly, a significantly greater percentage of these patients re-
ported clinical AEs than patients in the FA group (P < 0.001).
Overall, 29.9% (124/415) of the surveyed patients reported experiencing AEs,
all of which were extraskeletal and none of which were serious. Most of these
events were systemic and expected for this type of treatment (most commonly
fever and flu-like symptoms [eg, headache, malaise, fatigue, chills, and asthe-
nia]). Three patients exhibited mild ocular AEs: 1 patient complained of pain
and the other 2 had ocular redness secondary to conjunctivitis. Treatment with
pamidronate was discontinued in all 3 cases to avoid the possibility of exacer-
bating these complications. There were no reports of iritis, iridocyclitis, or
optic nerve involvement.
Biochemical Data
The FA and LFA groups were similar in terms of sex and age. Patients in the
LFA group received a cumulative dose of pamidronate that was approximately
half the dose of the FA group, and the frequency of their infusions was ~60%
lower. Nonetheless, the dose impact (cumulative dose/frequency of administra-
tion) was 21% higher in the FA group, which means that the difference between
Table I. Baseline demographic and clinical characteristics of study patients by fre-
quency of treatment with IV pamidronate.
FA Group LFA Group
Characteristic (n = 511) (n = 97) P
Age, mean (SD), y 69 (10) 70 (10) NS
Sex, no. (%) NS
Female 393 (77) 71 (73) NS
Male 118 (23) 26 (27) NS
Cumulative dose, mean (SD), mg/y 318 (156) 158 (26) <0.01
No. of infusions/patient, mean (SD) 5.4 (2.2) 3.3 (0.9) <0.03
FA = frequent administration; LFA = less frequent administration.
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cumulative doses was related more to the frequency of administration than to
the amount administered per dose. Patients in the FA group received lower
doses per infusion and more infusions per year.
Figures 1A–E show the changes in the biochemical variables; all variables
had steady means and 95% CIs. Mean (SD) PlatC in the LFA group did not change
significantly (count 1000/mL): 214.8 (46.6) at baseline, 223.4 (53.1) at 90 days,
Table II. Clinical adverse events (AEs) observed retrospectively in 415 patients treated
with intravenous pamidronate, according to clinical records confirmed by
telephone survey. Values are no. (%).
FA Group LFA Group Total
Reported AEs (n = 348) (n = 67) (N = 415)* P†
None 285 (81.8) 6 (8.9) 291 (70.1) <0.001
General
Fever 26 (7.5) 25 (37.3) 51 (12.3) <0.001
Headache 7 (2.0) 7 (10.4) 14 (3.4) <0.001
Malaise 5 (1.4) 2 (3.0) 7 (1.7) NS
Fatigue 2 (0.6) 3 (4.5) 5 (1.2) <0.007
Chills 3 (0.9) 2 (3.0) 5 (1.2) NS
Asthenia 1 (0.3) 4 (6.0) 5 (1.2) <0.001
Hypertension 0 3 (4.5) 3 (0.7) ‡
Rash 0 2 (3.0) 2 (0.5) ‡
Local
Pain 1 (0.3) 2 (3.0) 3 (0.7) ‡
Phlebitis 2 (0.6) 1 (1.5) 3 (0.7) ‡
Digestive
Nausea/vomiting 3 (0.9) 2 (3.0) 5 (1.2) NS
Diarrhea 3 (0.9) 2 (3.0) 5 (1.2) NS
Ocular
Redness 2 (0.6) 0 2 (0.5) ‡
Pain 1 (0.3) 0 1 (0.2) ‡
Neuromuscular
Myalgia/arthralgia 7 (2.0) 5 (7.5) 12 (2.9) <0.014
Cramps 0 (0.0) 1 (1.5) 1 (0.2) ‡
Total reported AEs 63 (18.1) 61 (91.0) 124 (29.9) –
FA = frequent administration; LFA = less frequent administration.
*Seven patients died after follow-up and prior to telephone interview: 6 patients from the FA group,
1 patient from the LFA group. 
†FA versus LFA (χ2 test).
‡Number of patients was too small to determine the P value.
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Figure 1. Mean (95% CI) biochemical and hematologic findings in patients treated
with less frequent administration (LFA) or frequent administration (FA) of IV
pamidronate in (A) serum creatinine (sCreat) and (B) white blood cell count
(WBCC). Data are reported from 90 days prior to treatment through follow-up,
up to 1 year. 
(continued)
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Figure 1. (Continued) Mean (95% CI) biochemical and hematologic findings in pa-
tients treated with less frequent administration (LFA) or frequent admin-
istration (FA) of IV pamidronate in (C) platelet count (PlatC), (D) aspartate
aminotransaminase (AST), and (E) alanine aminotransaminase (ALT). Data
are reported from 90 days prior to treatment through follow-up, up to 1
year. The PlatC in the FA group was not included because the percentage
of missing data was >20%. 
01_CTRV68N1_sarli  3/8/07  3:11 PM  Page 9
CURRENT THERAPEUTIC RESEARCH
10
and 222.6 (52.6) at 365 days. PlatC was not reported for the FA group because
the percentage of missing data was >20%.
Figures 2A and 2B show variations in serum calcium and serum 25-HVD lev-
els according to the pamidronate dose administered and the length of treatment.
There were no cases of hypocalcemia, and 3 patients with low serum 
25-HVD levels at baseline reached normal levels during treatment. Correlation
between calcium and serum 25-HVD levels was low (r = 0.11, P < 0.01; top surface
plot has a parallel shape). Serum 25-HVD levels increased, but not significantly,
with dose and treatment time (bottom surface plot has a diagonal shape), while
calcium levels remained stable over time and increased mildly with dose.
Individual Biochemical Variations
A transient but significant decrease in WBCC (previous measurement versus
lowest) was experienced by 73 (12.0%) patients (10 patients, >18.2%–20% [mild
decrease]; 40 patients, 21%–30%; 14 patients, 31%–40%; 7 patients, 41%–50%;
and 2 patients, >50%). The largest decrease in WBCC (55%) was seen in a 50-year-
old woman with Sudeck’s disease. The decrease was recorded 177 days after
administration of the first 45-mg dose (cumulative dose of 90 mg/y) and did not
reach a level consistent with leukopenia.
Leukopenia was found in 8 (1.3%) patients during treatment (Table III). In
these patients, a significant relationship was not established between the
decrease in WBCC and the cumulative dose, age, or disease. Only the baseline
WBCC was found to be associated with the magnitude of the decrease (r = 0.94;
P < 0.001). However, 5 of the 6 patients who were leukopenic prior to treatment
had a normal WBCC after pamidronate treatment (Table IV).
A significant decrease in PlatC was observed in 20 (3.3%) patients com-
pared with pretreatment values (3 patients, >16.2%–20%; 14 patients, 21%–30%;
and 3 patients, >30%). Table V shows data for the 5 patients who developed
thrombocytopenia (PlatC <150,000/mL). The greatest percentage decrease (36%)
occurred in a 58-year-old woman treated for Paget’s disease. The decrease was
recorded 177 days after infusion of pamidronate 45 mg, with a cumulative dose
of only 45 mg/y. Another patient who had a low baseline PlatC received a single
15-mg dose and responded with a larger absolute decrease in PlatC; treatment
was discontinued in that patient.
The sCreat level increased significantly (>8.13%) from baseline levels in
91 (15.0%) patients; this increase was transient in 79 (86.8%) patients and
permanent in the other 12 (Table VI). These patients required higher pami-
dronate doses due to their disease or presented other risk factors for the develop-
ment of renal failure. It should also be noted that 7 of the 12 patients had initi-
ated treatment with sCreat levels >1.20 mg/dL. Increases in sCreat levels in the
patients were distributed as follows: 25 patients, >8.13%–10.9%; 43 patients,
11%–20%; 19 patients, 21%–40%; 0 patients, 41%–50%; 1 patient, 51%–60%; 
1 patient, 61%–70%; 1 patient, 71%–80%; and 1 patient, >80%. The latter patient
was an 82-year-old man with Paget’s disease. His sCreat level increased 87%,
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Figure 2. Least squares adjusted surface plots of (A) serum 25-hydroxy vitamin D
(25-HVD) and (B) serum calcium levels based on the dose of pamidronate
cumulated to the biochemical assessment period, and by the length of
pamidronate treatment (months) in 608 patients receiving intravenous
doses of pamidronate. The surface average values are represented in the
clear zone. The dark zones represent the maximum and minimum SEM
limits.
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from 0.69 mg/dL at baseline to 1.29 mg/dL 245 days after his last 45-mg pami-
dronate infusion; his cumulative dose for that period was 225 mg and treatment
was discontinued thereafter. Thirteen patients had sCreat levels >1.20 mg/dL 
at the beginning of treatment. The levels did not change significantly in 7 patients
and fell below baseline values in the other 6 patients.
DISCUSSION
In general, bisphosphonates are an excellent option for the treatment of meta-
bolic osteopathies. Because of their effectiveness in reducing the risk for patho-
logic fractures, they have become first-choice drugs for the treatment of post-
menopausal osteoporosis. At present, alendronate and risedronate are the
most widely used oral bisphosphonates. Oral pamidronate, available in some
countries, has also been found to be effective29,30; however, it is associated with
a high prevalence of gastrointestinal AEs: 22.3% and 28.0% in the 2 largest trials
assessed.20,21 This suggests that parenteral administration might be used in
osteoporotic patients with gastroesophageal disorders. The therapeutic results
obtained in the present study might be compared with those obtained with oral
pamidronate and other bisphosphonates using variations in bone mineral den-
sity and/or biochemical markers of bone metabolism as therapeutic surro-
gates.12 For some conditions, such as Paget’s disease or bone metastases, the
doses required are higher than those used for the management of osteoporosis.
For this reason, parenteral administration is a good alternative for pamidronate
treatment.
This retrospective analysis of 608 patients treated with IV pamidronate
included 415 patients who were interviewed by telephone to confirm data
records and AEs. In this group, no serious AEs were reported, and the preva-
lence of clinical AEs was 29.9%, similar to the proportion observed with oral
regimens.20,21 Because the interviewed patients were a major part of the entire
cohort of patients, the prevalence of AEs in the entire study sample was also
presumed to be similar. It should be mentioned that telephone interviews were
conducted to avoid underestimating the occurrence of AEs; however, the possi-
bility that recall bias was introduced by this approach cannot be ruled out. The
seemingly paradoxical finding of a 4.6-fold higher percentage of reported AEs
with LFA treatment should be interpreted with caution because although doses
were less frequently administered, they were similar in magnitude (–21%) to
those of the FA group. In this regard, it is possible that the bisphosphonate frac-
tion that was rapidly adsorbed to bone mineral surface promoted therapeutic
benefits, while the fraction not linked to bone might have induced undesirable
systemic events. Therefore, higher skeletal uptake in patients with more severe
medical conditions may lower the probability of AEs. Patients with serious ill-
nesses, whose bisphosphonate uptake by bone was ~4 times greater than that
of less affected patients,6 were more likely to have been included in the FA
group. Patients who discontinued their treatment prematurely, perhaps due to
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AEs, were more likely to have been included in the LFA group. It is also possible
that osteoporotic patients with low bone turnover rates might have received
relatively excessive doses and thus may have had more bisphosphonate avail-
able to target soft tissues. Therefore, the relationship between the AE rate and
the frequency of study drug administration cannot be completely defined by
this study.
The most frequent AEs were fever and flu-like symptoms (eg, cephalea,
malaise, fatigue, chills, and asthenia) which was reported by 20.9% (87/415) 
of the patients, probably due to idiosyncratic sensitivity or to acute phase reac-
tions. Other AEs of pamidronate have been reported in the literature; some of
them were severe, such as ototoxicity,8 ocular complications,9,11 and, less fre-
quently, nephrotic syndrome and renal failure.10 Ocular complications reported
include anterior uveitis, scleroiritis, episcleritis, and nonspecific transient con-
junctivitis, all occurring with varying degrees of severity.9,11 In our study, mild
ocular reactions were observed in 0.7% (3/415) patients, supporting the esti-
mate that the prevalence of ocular AEs is <1%.11 Because these symptoms often
recur after the administration of a new dose, it was decided to discontinue
pamidronate treatment in these patients.
Osteonecrosis of the jaw has been reported in patients treated with IV and
high-dose oral bisphosphonates.31–33 This was not the case in our sample,
which only included 6 patients with malignant diseases, a key predisposing fac-
tor for this complication. Low calcium levels caused by high doses of bisphos-
phonates also seem to promote jaw osteonecrosis,34 but the treatment sched-
ule and the doses of pamidronate administered to those 6 patients did not
greatly depress their bone metabolism.
The development of nephrotic syndrome with marked renal function
impairment has been described in cancer patients treated with high doses of
bisphosphonate.10 In all those patients treatment was initiated at the re-
commended dosage of 90 mg/month, but the dosage was later raised to 
180 mg/month and in some cases even to 360 mg/month. Kidney biopsies of
these patients suggested glomerulosclerosis with focal and segmental col-
lapse, significant degenerative tubular changes, and formation of tubular
microcysts. Electron microscopy studies suggested diffuse loss of the cytoar-
chitecture of podocytes, with disappearance of primary processes and pedi-
cles. The authors speculate that, because bisphosphonates can modify the
cytoskeleton in osteoclasts by inhibiting the assembly of actin rings, they
might have a similar effect on podocytes. Furthermore, the high concentra-
tions reached both in kidney and in bone might favor the occurrence of the
toxic effects of pamidronate.10 In our experience, the increase in sCreat level
was the most common biochemical AE, occurring in 15.0% of the patients. It
should be noted that the criterion we used for significance is probably high,
as it required an increase of >8.13% with respect to previous levels. And,
although sCreat levels increased in most cases, they nonetheless remained
within the normal range. Even in the patient who had the greatest increase in
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sCreat level (87%), the absolute level reached did not exceed 1.29 mg/dL.
Twelve patients developed persistent renal function damage; 1 of these patients
had been treated for osteoporosis and 9 were associated with the greatest
increase when their cumulative dose of pamidronate was <180 mg. However, no
case of nephrotic syndrome or marked decrease in glomerular filtration rate
was detected. We should emphasize that the patients who exhibited a perma-
nent increase in sCreat level also had other risk factors for renal function
impairment (eg, advanced age, diabetes, multiple myeloma, and urinary
obstructive disease).
Mean values for liver serum transaminase activities, PlatC, sCreat level, and
WBCC did not change significantly when compared with baseline levels.
Nonetheless, 1.3% of the patients treated had significant but transient leukope-
nia and 0.8% had thrombocytopenia. In a previous study conducted by our
group,20 when pamidronate was administered orally to 635 osteoporotic
women, 7.4% of the patients developed leukopenia, 2.0% experienced hemato-
logic disorders (eg, mild thrombocytopenia), and only 0.6% of the patients had
a reduction in hematocrit. In the present study, all cases of hematologic AEs
were self-limited, and none required discontinuation of treatment. Five of 6 pa-
tients were of special interest, because they were leukopenic at the initiation of
treatment, but their WBCCs increased spontaneously after the first pamidronate
infusion. This might suggest that the risk for hematologic AEs does not increase
when pamidronate is administered IV.
Patients with previous conditions, such as leukopenia and elevated sCreat
levels (Tables IV and VI) were also of special interest, because most of them
had favorable outcomes. Nonetheless, both of these laboratory findings are rel-
ative contraindications for the use of pamidronate in severe osteopathies.
Therefore, the drug should be avoided when treating osteoporotic patients with
these disorders. We were surprised to find that pamidronate has been pre-
scribed under such circumstances; however, these reports were found among
the earliest data recorded on this subject, and exposure to pamidronate
occurred incidentally. Publication of these cases, which would add to the
knowledge of pamidronate tolerability, is rare in the medical literature.
CONCLUSIONS
Pamidronate administered IV was well tolerated when used for treating osteo-
porosis or other metabolic osteopathies in our study population. The clinical
AEs observed with IV pamidronate administration were not serious and hema-
tologic changes were mild, transient, and not associated with dose, time of
treatment, or any particular underlying disease. An increase in sCreat level was
the most frequent biochemical complication and was found in patients with
additional risk factors for renal failure and particular diseases. Whether certain
patients with risk factors for osteoporosis may require even fewer IV adminis-
trations of the drug is an issue that remains to be elucidated. 
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